iBio, Inc. Files 8-K: Financials and Operations Update
Ticker: IBIO · Form: 8-K · Filed: 2024-11-12T00:00:00.000Z
Sentiment: neutral
Topics: financial-results, operations, sec-filing
Related Tickers: IBIO
TL;DR
IBIO filed an 8-K on Nov 12, 2024, updating financials. Check it out.
AI Summary
On November 12, 2024, iBio, Inc. filed an 8-K report detailing its financial results and condition. The company, formerly known as iBioPharma, Inc. and InB:Biotechnologies, Inc., is incorporated in Delaware and headquartered in New York, NY. The filing pertains to the period ending November 12, 2024.
Why It Matters
This 8-K filing provides crucial updates on iBio, Inc.'s financial condition and operational status, which is essential for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful review by investors.
Key Numbers
- 001-35023 — SEC File Number (Identifies the company's filing with the SEC.)
- 26-2797813 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- iBio, Inc. (company) — Registrant
- November 12, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- New York, NY (location) — Business Address
- iBioPharma, Inc. (company) — Former Company Name
- InB:Biotechnologies, Inc. (company) — Former Company Name
FAQ
What specific financial information is being reported in this 8-K filing?
This 8-K filing is primarily an update on the company's financial condition and results of operations, as indicated by the 'ITEM INFORMATION: Results of Operations and Financial Condition' section.
When was iBio, Inc. incorporated, and where is its principal executive office located?
iBio, Inc. was incorporated in Delaware, and its principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.
What were the previous names of iBio, Inc.?
iBio, Inc. was formerly known as iBioPharma, Inc. and InB:Biotechnologies, Inc.
What is the filing date of this 8-K report?
The filing date of this 8-K report is November 12, 2024.
What is the SIC code for iBio, Inc.?
The Standard Industrial Classification (SIC) code for iBio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-11-12 16:06:21
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value per share IBIO NYSE Americ
Filing Documents
- ibio-20240930x8k.htm (8-K) — 31KB
- ibio-20240930xex99d1.htm (EX-99.1) — 15KB
- 0001420720-24-000053.txt ( ) — 174KB
- ibio-20240930.xsd (EX-101.SCH) — 4KB
- ibio-20240930_def.xml (EX-101.DEF) — 4KB
- ibio-20240930_lab.xml (EX-101.LAB) — 14KB
- ibio-20240930_pre.xml (EX-101.PRE) — 10KB
- ibio-20240930x8k_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 12, 2024, iBio, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished with this Current Report on Form 8-K. Exhibit Number Exhibit Description 99.1 Press Release, issued by iBio, Inc. dated November 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 12, 2024 IBIO, INC. By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: Chief Legal Officer